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disorder named cholesteryl ester storage disease (CESD) or the more severe form of Wolman’s disease, is an important
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hypercholesterolaemia or mixed hyperlipidaemia predisposing to premature atherosclerosis, as well as liver dysfunction,
which can lead to cirrhosis and liver failure. Diagnosis can be made through genetic screening, LAL activity measurement or
on liver biopsy. Recent advances in treatment of LAL deficiency have been made with development of a recombinant
human LAL (sebelipase alpha). Adjunctive treatment with lipid-lowering therapy continues to be standard management.
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Introduction
Cholesteryl ester storage disease (CESD) is a rare, autosomal
recessive lysosomal storage disorder, resulting from a deficiency
in lysosomal acid lipase (LAL) activity. LAL deficiency results in
accumulation of cholesteryl esters and triglycerides in multiple
body tissues, the clinical manifestations and complications of
which can present from as early as the first year of life. Although
a rare condition, the likelihood is that many patients go unrecog-
nised or are misdiagnosed. In this report, we present a case of an
adult female who initially presented, and was subsequently
diagnosed, at the age of four years.
Case
At the time of presentation to the Division of Endocrinology &
Metabolismat theCharlotteMaxeke JohannesburgAcademicHos-
pital (CMJAH), the patient, a 31-year-old female, was soon to be
married. She had been living (and receivingmedical care) in Singa-
pore but had recently relocated with her husband-to-be to Johan-
nesburg and required ongoing medical care for her condition.
The patient is originally from Germany. At the age of four years,
she presented with hepatosplenomegaly and, following a liver
biopsy, was diagnosed with CESD. At that time, lipid-lowering
therapy was initiated in the form of an HMG-CoA reductase
inhibitor (simvastatin/atorvastatin), which she continued until
the age of 19 years when she opted to stop treatment. Four
years later, when her father died unexpectedly (at the age of
52 years) she restarted lipid-lowering therapy and was on ator-
vastatin 80 mg daily at presentation.
Further inquiry revealed that she had been a smoker, having
stopped two years previously; had a modest alcohol intake
and underwent surgical intervention for a left ovarian cyst five
years earlier. She has no siblings and could provide little detail
regarding her extended family’s medical history. During her
routine follow-up, she had been informed that the size of her
liver and spleen had decreased on statin therapy. She had a
normal effort tolerance and no history of angina pectoris.
Clinically, she displayed no arcus cornealis, xanthelasma or
thickening of her Achilles tendons. She had a firm hepatomegaly
palpable 3 cm below the costal margin but the spleen was not
palpable. Significantly, she had a grade 3/6 ejection systolic
murmur over the aortic area, radiating to the neck, suggestive
of aortic stenosis.
Biochemical tests at the time of presentation revealed a total
cholesterol (TC) level of 3.9 mmol/l; triglycerides (Trig)
of 1.1 mmol/l; high density lipoprotein-cholesterol (HDLC) of
0.8 mmol/l and low-density lipoprotein cholesterol (LDLC) of
2.6 mmol/l. Furthermore, liver function tests showed mildly elev-
ated transaminases, aspartate transaminase (AST) of 69 U/l (RR
5–40) and alanine transaminase (ALT) of 92 U/l (RR 5–40) with
normal levels of alkaline phosphatase (ALP) of 48 U/l (RR 40–
120) and gamma-glutamyl transferase (GGT) of 29 U/l (RR 0–35).
At 24 years of age, she had undergone an ultra-fast CT scan,
which confirmed the presence of coronary calcification. At this
point, the course of action decided upon was to aim to decrease
the LDLC level further to < 2.6 mmol/l and to consider ezetimibe
therapy in conjunction with high-intensity statin therapy. Fur-
thermore, a cardiac assessment was requested, genetic testing
discussed, and she was advised to discontinue statin therapy
for the first trimester of a planned pregnancy.
The patient fell pregnant seven months later, having discontin-
ued statin therapy in the same month. She was advised to
remain off statin therapy for the duration of her pregnancy
and to reinitiate lipid-lowering therapy post-partum. The preg-
nancy progressed well although symptomatic palpitations
necessitated a cardiac assessment, which confirmed some calci-
fication and thickening of the aortic valve and ascending aorta,
causing minimal stenosis and an ejection fraction of 70%.
A healthy baby boy entered the patient’s life. During pregnancy
her cholesterol levels progressively increased and her lipogram
at delivery, off any lipid-lowering therapy, revealed a TC of
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16.53 mmol/l, Trig of 4.41 mmol/l, HDLC of 0.64 mmol/l and an
LDLC of 13.85 mmol/l. Having been advised to restart the
statin three months post-delivery, her repeat lipogram and
liver function just prior to re-initiation of therapy showed mark-
edly elevated cholesterol levels and increased transaminases (TC
14.38 mmol/l; Trig 2.84 mmol/l; HDLC 0.82 mmol/l; LDLC 12.27
mmol/l; ALT 103 IU/l; AST 74 IU/l; ALP 113 IU/l; GGT 34 IU/l). Ator-
vastatin 80mg daily was restarted.
Post-partum cardiac assessment revealed no significant differ-
ence in her status and a carotid duplex doppler study displayed
minimal plaque bilaterally with no increase in intimal thickening.
Within six months of restarting the statin, her LDLC dropped by
almost fourfold, with an associated improvement in her trigly-
ceride and liver function (TC 4.48 mmol/l; Trig 1.43 mmol/l;
HDLC 0.75 mmol/l; LDLC 3.08 mmol/l; ALT 67 IU/l; AST 48 IU/l).
Just over a year after restarting statin treatment, the patient
opted to interrupt therapy again in order to try for a second
child. Unfortunately, the second pregnancy remained elusive
and after having been off all lipid-lowering therapy for a full
year and watching rising lipid levels, lipid-lowering therapy
was recommenced.
Despite high-dose atorvastatin, her LDL remained persistently
above 3 mmol/l. It was decided to change to rosuvastatin in
an attempt to further lower the LDLC level. Disappointingly,
the patient seemed to respond sub-optimally to high-dose rosu-
vastatin (40 mg), with her LDLC rising to 5.4 mmol/l, and she was
switched back to atorvastatin.
After halting therapy for a time once more, in an attempt to
achieve conception, the patient subsequently continued ator-
vastatin without further significant improvement in her LDLC
levels (hovering around 3 mmol/l). Further cardiac review con-
firmed premature atherosclerosis with coronary calcification
and calcific aortic stenosis, as well as plaque in both her
carotid and femoral arteries. It was therefore considered essen-
tial that her hypercholesterolaemia be treated more aggres-
sively. Ezetimibe 10 mg daily was thus added to her therapy.
At this time her levels reflected the following: TC 4.8 mmol/l;
Trig 1.4 mmol/l; HDLC 1 mmol/l; LDLC 3.3 mmol/l; ALT 63 IU/l;
AST 55 IU/l.
Approximately a year later, a significant improvement in both
lipid and liver function tests was apparent. Her lipid profile
showed a TC of 3.3 mmol/l, Trig of 1 mmol/l, HDLC of 1mmol/l
and a LDLC of 1.8 mmol/l, while her transaminases were only
minimally elevated (ALT 44 IU/l; AST 39 IU/l).
For the past two years, the patient has been on a combination of
atorvastatin and ezetimibe with her lipid levels at target. She
continues to enjoy good cardiac health, with mild progression
of the aortic valve disease but, importantly, no evidence of
underlying ischaemia. She will require ongoing follow-up and
may require aortic valve replacement at some point in future.
As prior genotyping has not been performed for this patient, it
may be a further consideration in view of her son’s future risk
(Table 1).
Discussion
CESD is an autosomal recessive lysosomal storage disorder that
arises from loss of function mutations in the lysosomal acid
lipase gene (LIPA), which causes a deficiency in LAL activity.
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enzyme that hydrolyses cholesteryl ester and triglycerides deliv-
ered to the lysosome (Figure 1).1,2
A deficiency in LAL results in accumulation of cholesteryl esters
and, to a lesser extent, triglycerides in hepatocytes, spleen,
adrenal glands, intestines and the macrophage-monocyte
system of the body. The extent of involvement of the organs
reflects their contribution in the receptor-mediated endocytosis
and lysosomal degradation of lipoproteins.1
CESD is a rare, under-diagnosed disease with estimates of preva-
lence ranging from 1/40 000–1/300 000.4 The disorder can phe-
notypically manifest in two ways, namely the fulminant,
infantile-onset Wolman’s disease (WD) and the later-onset spec-
trum of CESD.
WDoccurs when LAL activity is completely absent or less than 1%
of normal activity. It presents within the first few months of life
with extensive lysosomal accumulation of cholesteryl esters
and triglycerides, resulting in hepatosplenomegaly, with associ-
ated liver disease, andmalabsorption from intestinal villi involve-
ment. Feeding difficulties, persistent emesis and malabsorptive
diarrhoea results in malnutrition and growth retardation.
Approximately half of patients haveadrenal calcification resulting
in adrenal insufficiency. The severity of the disorder is reflected by
ultimate mortality within the first year of life unless successfully
treated with haematopoietic stem cell transplantation.1, 5
CESD, later in onset, can present as a spectrum of disease
depending on the extent of LAL deficiency. It may present in
early childhood with features similar to WD with failure to
thrive and delayed milestones. More often, it remains unrecog-
nised, and the patient may present with elevated serum lipids
(LDLC and Trig) and/or hepatosplenomegaly that may be associ-
ated with elevated liver enzymes. This usually significantly pre-
dates the diagnosis. The morbidity and mortality of CESD
arises from the premature atherosclerosis resulting in coronary
artery disease or cerebrovascular events; associated liver dys-
function and ultimately liver failure; complications of secondary
hypersplenism as well as malabsorption from lipid deposition in
the intestinal tract.1,5
Due to the broad clinical spectrum of the disease as well as its
rarity, CESD often goes unrecognised or diagnosis is delayed,
hence it is thought to be an under-diagnosed condition. Patients
typically present with hepatomegaly and liver dysfunction (elev-
ated serum transaminases) or type IIB hyperlipoproteinemia
(elevated serum LDLC and Trig, with normal to low HDLC). Con-
tinuous lipid deposition leads to hepatic fibrosis, micronodular
cirrhosis and, eventually, liver failure.
The unexplained liver abnormalities may lead to a liver biopsy.
Grossly, the liver appears bright yellow-orange in colour and,
histologically, enlarged lipid-laden hepatocytes and macro-
phages with microvesicular steatosis are seen. A pathognomo-
nic feature, which can be elucidated by ultrastructural
examination, is the presence of the needle-shaped, lysosomal
CE crystals. Through immunostaining for the membranous
and luminal lysosomal proteins, LAMP2 and cathepsin D
respectively, the histologic diagnosis of CESD can be improved
upon.1
It is, however, possible that the diagnosis may be missed, being
commonly mistaken and misclassified as either non-alcoholic
fatty liver disease (NAFLD), non-alcoholic steatohepatitis
(NASH), or even cryptogenic liver disease. NAFLD is usually
associated with central obesity. It is, therefore, imperative that
clinical aspects are taken into account—particularly waist cir-
cumference and body mass index, especially when considering
such a diagnosis in a lean individual.5
The clinical manifestations of CESD allow for a number of other
differentials. In light of the hepatosplenomegaly, these may
include other storage disorders, including other lysosomal
storage disorder (such as mucolipidosis II, mucopolysacchari-
doses, Gaucher’s disease and Nieman–Pick disease types A
and B) as well as glycogen storage diseases. In view of the
lipid abnormalities, familial hypercholesterolaemia and autoso-
mal recessive hypercholesterolaemia may be considered but
hepatomegaly does not occur in these conditions.5
Associated clinical and biochemical features can be used to dis-
tinguish the diagnosis. For example, although the lipid profile
may be similar in Nieman–Pick, the interstitial lung disease
and the ophthalmologic findings are not seen in LAL deficiency.
In Gaucher’s disease the lipid abnormalities, bone manifes-
tations and adrenal calcifications are not apparent. And while
the contractures, skeletal dysplasia and coarse facial features
Figure 1: Cellular cholesterol homeostasis in healthy individuals and patients with LAL deficiency.
Abbreviations: ACAT = acyl-CoA: cholesterol acyltransferase; CE = cholesterol ester; FA = fatty acid; FC = free cholesterol; HMG-SoAr = 3-hydroxy-3-methyl-glutaryl.CoA
reductase; LDL-C = low-density lipoprotein cholesterol; LDLR = low density lipoprotein remnant; SREBPs = sterol regulatory element binding proteins; TG = triglyceride;
VLDL-C = very low-density lipoprotein cholesterol.3
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are typical of mucolipidosis II and mucopolysaccharidoses, they
are not features of CESD. The same can be said of the hypogly-
caemia, kidney dysfunction and cardiomyopathy associated
with the glycogen storage diseases.5
The diagnosis of CESD can be confirmed through genetic
screening and identification of either biallelic pathogenic var-
iants of LIPA or testing for deficiency in LAL enzyme activity.
As over 40 loss-of-function mutations in the LIPA gene have
been reported, one could consider a number of molecular
testing methods. First, single gene testing, which consists of
sequence analysis of the LIPA gene. Second, a multigene
panel, which assesses the LIPA gene and other genes of interest.
And third, comprehensive genomic testing can be considered in
patients with features of LAL in whom the single/multi-gene
testing were unsuccessful in identifying a mutation. If available,
this includes genome sequencing as well as mitochondrial
sequencing.5, 6
In assessment of deficiency in LAL enzyme activity, the diagnos-
tic test is the assay measuring LAL activity in peripheral blood
leukocytes. However, enzyme activity can also be measured in
hepatocytes, fibroblasts or dried blood spots. Residual LAL
activity varies according to the severity of the disease with
Wolman’s disease usually estimated at less than 5% of normal
activity and CESD ranging between 2% and 11%.5–7
Unfortunately, neither the genetic nor the enzymatic testing is
available in South Africa. Although cost is likely prohibitive, it
is possible for the enzymatic test to be performed on a dried
blood spot sample sent to an international laboratory. Once
the diagnosis is made non-invasively, a liver biopsy may be
done for staging and to monitor progression of the disease. It
is, however, more likely, considering our resources in South
Africa, that both diagnosis and staging will have to be confirmed
by liver biopsy.
Treatment of patients with LAL deficiency, until recently, mainly
focused on symptomatic management of the disorder. It was
only in 2015 that the United States Food and Drug Adminis-
tration (FDA) approved enzyme replacement therapy (ERT)
with sebelipase alpha. Sebelipase alpha is a recombinant
human LAL, with the same amino acid sequence as that of
human LAL. The enzyme is attached to mannose, allowing deliv-
ery to the lysosome via mannose-6-phosphate receptors.5, 8
In a randomised placebo-controlled, phase 3 study in children
and adults with LAL deficiency, sebelipase alpha treatment
was associated with significantly higher rates of normalisation
in ALT and AST levels compared with placebo. Furthermore, a
reduction in hepatic fat content and improvement in LDLC,
HDLC and Trig levels was demonstrated. It was shown that
ERT may be life-saving in WD and both improve and prolong
life in CESD.9 Recently, a study evaluating sebelipase alpha’s
impact on atherogenic biomarkers in children and adults with
LAL deficiency appeared positive.8 Treatment with sebelipase
alpha (irrespective of lipid-lowering therapy use) reflected
improved atherogenic biomarkers, particularly significant
decreases in mean LDL particle number, LDLC levels and
ApoB levels as well as significant increases in mean HDLC
and ApoA1 levels compared with placebo. This reflects an
improvement in the atherogenic profile of patients with LAL
deficiency, and hence improved cardiovascular disease risk.8
Sebelipase alpha is, unfortunately, currently not available in
South Africa.
There was a paucity of treatment guidelines for LAL deficiency
prior to the FDA approval of sebelipase alpha. Lipid-lowering
therapy, in the form of statins, ezetimibe and/or cholestyramine,
as well as a low-fat, low-cholesterol diet, was (and still are) often
used to treat the dyslipidaemia associated with the disorder and
alleviate the atherogenic risk. In advanced disease, liver and hae-
mopoietic stem cell transplantation have been undertaken with
significant associated morbidity and limited success. It must be
noted that all these therapeutic interventions do not address the
underlying mechanism or the multisystem nature of the disease
and, hence, have limited efficacy.5,8
Furthermore, the importance of genetic counselling has to be
stressed in order to equip both the patient and the family
with adequate knowledge of the nature, inheritance and impli-
cations of the disease. This will also facilitate the screening of off-
spring of the affected patients.
When discussing rare diseases such as LAL deficiency, one has to
consider the cost that diagnosis and management would entail,
especially in a resource-constrained setting such as South Africa.
Drugs that are developed for rare diseases are often extremely
expensive on a cost-per-patient basis. Complications that arise
from such a disease, such as liver failure or cardiovascular com-
plications, also require significant resource outlay. Analysis of the
pharmacoeconomics associated with the cost-effectiveness of a
treatment such as ERT would thus be of interest.10 A recent
study in the United Kingdom evaluated the costs of managing
children and adults with LAL deficiency in a tertiary centre,
and found these to be staggering. In light of this, consideration
needs to be given to rare diseases in policy and budgetary
decision-making.11
Conclusion
LAL deficiency is a rare genetic, multi-systemic disorder. It is an
unusual cause of liver dysfunction, associated with dyslipidae-
mia and increased atherogenic risk, that eventually results in
liver failure. Increased awareness of LAL deficiency by healthcare
workers including hepatologists, pathologists, endocrinologists,
cardiologists and neurologists will result in improved detection
of patients, leading to earlier treatment and improved
outcome. A high index of suspicion in lean patients who
present with the constellation of signs including hypercholester-
olaemia, hepatomegaly and abnormal liver enzymes may make
early identification of this disease more likely. Establishing the
diagnosis is imperative, now more than ever, due to the devel-
opment of a new therapeutic approach in the form of recombi-
nant human LAL, an enzyme replacement therapy.
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